Stock Evaluator: Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. JANX

$10.08 -0.21 -2.04%
November 20, 2026 4:00:00 PM EST November 10, 2021 Volume: 1,114,709
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Commentary & Analysis


Financial Summary

Share Statistics JANX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $617.0 $203.5 41%
Shares Out (Mil) 63.1 55.2 52%
Institutional Ownership 98.7% 93.3% 81%
Float (Mil) 45.6 40.4 44%
Beta 2.39 1.05 95%
Avg Daily Volume (000s) 1,455 569 75%
Price Change
(52-week)
(65.0%) 38.8% 15%
Growth JANX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) (75.6%) (10.7%) 3%
EPS (5yr) 24.4% 15.4% 75
Dividends (5yr) na 0.0% 0%
Cash Flow (5yr) (22.7%) (15.7%) 29%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 15 15 14
Current EPS ($0.511) ($1.574) ($2.552)
Month Ago EPS ($0.566) ($1.732) ($2.624)
# Rev Up 0 0 0
# Rev Down 4 1 1
Three Months Ago EPS ($0.585) ($1.758) ($2.639)
Year/Year Chg 49.4% (14.2%) 76.4%
Financials JANX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $23 $40 14%
Net Income (TTM) (Mil) ($100) ($44) 11%
EPS (TTM) ($1.592) ($1.400) 16%
Operating Cash Flow (TTM) (Mil) ($54) ($35) 9%
Net Cash Flow (TTM) (Mil) ($7) $-0 35%
Long-Term Debt (Q1) (Mil) $18 $4 32%
Enterprise Value (Q1) (Mil) $153 $142 25%
Valuation JANX Industry
Median
Percentile
(All Stocks)
P/B 0.68 1.96 18%
P/E na 16.9 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 0.9 na
Ratios JANX Industry
Median
Percentile
(All Stocks)
Gross Margin (414.9%) 67.6% 0%
Net Margin (428.7%) (50.8%) 2%
ROA (9.9%) (47.0%) 25%
ROE (10.6%) (51.8%) 27%
Liabilities to Assets 7.3% 29.6% 4%
F-Score 3 3 18%

Janux Therapeutics, Inc. did not pass any screens on 11/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors